2022 World Conference on Lung Cancer (ePosters)-EP05.02-010. Robotic-Assisted Thoracic Surgery Following Neoadjuvant Chemoimmunotherapy in Patients with Stage III Non-small Cell Lung Cancer

EP05.02-010. Robotic-Assisted Thoracic Surgery Following Neoadjuvant Chemoimmunotherapy in Patients with Stage III Non-small Cell Lung Cancer

Back to course

Pdf Summary

A new study evaluated the feasibility and safety of robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage non-small cell lung cancer (NSCLC). The study included 44 patients who underwent robotic-assisted thoracic surgery after receiving neoadjuvant chemoimmunotherapy, and their pathological response to the treatment and surgical outcomes were evaluated. The results showed that 81.8% of the patients had a major pathological response and 59.1% had a pathological complete response based on surgical specimen examination. The study also found that robotic-assisted thoracic surgery was performed successfully in all patients, with only 4.5% requiring conversion to thoracotomy. Treatment-related adverse events occurred in 18.2% of the patients, but there were no unexpected perioperative complications or mortality within 90 days after the surgery. The study concluded that robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy is a feasible and safe therapeutic option for patients with stage NSCLC. However, further confirmation is needed through large-scale clinical trials.

Asset Subtitle

Min Li

Meta Tag

Speaker Min Li

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

robotic-assisted thoracic surgery

neoadjuvant chemoimmunotherapy

non-small cell lung cancer

feasibility

safety

pathological response

surgical outcomes

major pathological response

pathological complete response

conversion to thoracotomy